Libero Santarpia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/850404/publications.pdf

Version: 2024-02-01

66	5,114	109321	123424
papers	citations	35 h-index	61 g-index

66	66	66	9905
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Targeting the MAPKâ€“RASâ€“RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 103-119.	3.4	740
2	miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Research and Treatment, 2016, 160, 439-446.	2.5	678
3	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 2012, 118, 2603-2614.	4.1	265
4	Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer. Journal of the National Cancer Institute, 2011, 103, 264-272.	6.3	203
5	A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients. Clinical Cancer Research, 2015, 21, 1207-1214.	7.0	191
6	Phosphatidylinositol 3-Kinase/Akt and Ras/Raf-Mitogen-Activated Protein Kinase Pathway Mutations in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 278-284.	3.6	177
7	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nature Reviews Clinical Oncology, 2013, 10, 377-389.	27.6	164
8	Targeting microRNAs as key modulators of tumor immune response. Journal of Experimental and Clinical Cancer Research, 2016, 35, 103.	8.6	160
9	Missense Mutation in the Transcription Factor NKX2â€“5: A Novel Molecular Event in the Pathogenesis of Thyroid Dysgenesis. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1428-1433.	3.6	157
10	Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. International Journal of Cancer, 2016, 138, 87-97.	5.1	136
11	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget, 2015, 6, 37269-37280.	1.8	135
12	Prolylâ€isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Molecular Medicine, 2014, 6, 99-119.	6.9	130
13	Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 386-391.	3.6	120
14	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle, 2013, 12, 1679-1687.	2.6	109
15	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment, 2012, 134, 333-343.	2.5	106
16	Targeting triple negative breast cancer: Is p53 the answer?. Cancer Treatment Reviews, 2013, 39, 541-550.	7.7	106
17	Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis. Journal of Thoracic Oncology, 2022, 17, 103-115.	1.1	89
18	Breast cancer assessment tools and optimizing adjuvant therapy. Nature Reviews Clinical Oncology, 2010, 7, 725-732.	27.6	83

#	Article	IF	Citations
19	Uncovering the metabolomic fingerprint of breast cancer. International Journal of Biochemistry and Cell Biology, 2011, 43, 1010-1020.	2.8	77
20	DNA Repair Gene Patterns as Prognostic and Predictive Factors in Molecular Breast Cancer Subtypes. Oncologist, 2013, 18, 1063-1073.	3.7	75
21	A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocrine-Related Cancer, 2013, 20, 809-823.	3.1	74
22	Genetic alterations in the RAS/RAF/mitogenâ€activated protein kinase and phosphatidylinositol 3â€kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. Cancer, 2010, 116, 2974-2983.	4.1	70
23	Notch is a direct negative regulator of the DNA-damage response. Nature Structural and Molecular Biology, 2015, 22, 417-424.	8.2	68
24	TP53 mutationâ€correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53â€mutated breast cancers. Molecular Oncology, 2014, 8, 508-519.	4.6	59
25	Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer. Cancer Research, 2010, 70, 8852-8862.	0.9	58
26	The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors. Endocrine Reviews, 2010, 31, 578-599.	20.1	56
27	MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. Endocrine-Related Cancer, 2010, 17, F51-F75.	3.1	53
28	Homologies Between Proteins of Borrelia burgdorferi and Thyroid Autoantigens. Thyroid, 2004, 14, 964-966.	4.5	49
29	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Research, 2013, 15, R86.	5.0	44
30	Human Thyroid Autoantigens and Proteins ofYersiniaandBorreliaShare Amino Acid Sequence Homology That Includes Binding Motifs to HLA-DR Molecules and T-Cell Receptor. Thyroid, 2006, 16, 225-236.	4.5	43
31	Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer. Oncologist, 2016, 21, 1063-1078.	3.7	41
32	AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients. Npj Breast Cancer, 2016, 2, 16033.	5.2	41
33	High Resolution Array-Comparative Genomic Hybridization Profiling Reveals Deoxyribonucleic Acid Copy Number Alterations Associated with Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4367-4372.	3.6	39
34	RET TKI: Potential Role in Thyroid Cancers. Current Oncology Reports, 2012, 14, 97-104.	4.0	38
35	Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Human Pathology, 2008, 39, 15-20.	2.0	37
36	Targeting the microRNA-regulating DNA damage/repair pathways in cancer. Expert Opinion on Biological Therapy, 2014, 14, 1667-1683.	3.1	36

#	Article	IF	Citations
37	Inhibition of pituitary tumorâ€transforming geneâ€1 in thyroid cancer cells by drugs that decrease specificity proteins. Molecular Carcinogenesis, 2011, 50, 655-667.	2.7	35
38	Cellular Signaling Pathway Alterations and Potential Targeted Therapies for Medullary Thyroid Carcinoma. International Journal of Endocrinology, 2013, 2013, 1-16.	1.5	34
39	Progress in nonviral gene therapy for breast cancer and what comes next?. Expert Opinion on Biological Therapy, 2017, 17, 595-611.	3.1	32
40	The role of topoisomerase IÎ± and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treatment Reviews, 2009, 35, 662-667.	7.7	30
41	Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Human Pathology, 2009, 40, 827-833.	2.0	28
42	Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer. Cytokine, 2012, 59, 218-222.	3.2	26
43	An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes. British Journal of Cancer, 2018, 118, 1107-1114.	6.4	26
44	Lymphocytic Hypophysitis: Differential Diagnosis and Effects of High-Dose Pulse Steroids, Followed by Azathioprine, on the Pituitary Mass and Endocrine Abnormalities â€" Report of a Case and Literature Review. Scientific World Journal, The, 2010, 10, 126-134.	2.1	24
45	Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head and Neck, 2009, 31, 419-423.	2.0	23
46	Mosaicism in von Hippelâ€Lindau disease: an event important to recognize. Journal of Cellular and Molecular Medicine, 2007, 11, 1408-1415.	3.6	22
47	Four Patients with Cutaneous Metastases from Medullary Thyroid Cancer. Thyroid, 2008, 18, 901-905.	4.5	20
48	Integrated MicroRNAâ€“mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 194.	4.1	18
49	Adjuvant systemic treatment for individual patients with triple negative breast cancer. Breast, 2011, 20, S135-S141.	2.2	14
50	Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. Breast, 2012, 21, 336-342.	2.2	12
51	PIK3CA Mutations and BRCA1 Expression in Breast Cancer: Potential Biomarkers for Chemoresistance. Cancer Investigation, 2008, 26, 1044-1051.	1.3	11
52	Triple negative breast cancer: a heterogeneous subgroup denned by what it is not. European Journal of Cancer, 2011, 47, S370-S372.	2.8	11
53	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. Journal of Cancer, 2017, 8, 1045-1052.	2.5	9
54	Targeted Therapy for Endocrine Cancer: The Medullary Thyroid Carcinoma Paradigm. Endocrine Practice, 2009, 15, 597-604.	2.1	7

#	Article	IF	Citations
55	Germline Mutation of von Hippel-Lindau (VHL) Gene 695 G>A (R161Q) in a Patient with a Peculiar Phenotype with Type 2C VHL Syndrome. Annals of the New York Academy of Sciences, 2006, 1073, 198-202.	3.8	5
56	Primary growth hormone insensitivity (Laron syndrome) and acquired hypothyroidism: a case report. Journal of Medical Case Reports, 2011, 5, 301.	0.8	5
57	Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers. Current Pharmaceutical Design, 2013, 19, 864-882.	1.9	5
58	Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer. Future Oncology, 2011, 7, 173-186.	2.4	4
59	Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers. Current Pharmaceutical Design, 2013, 19, 864-82.	1.9	3
60	A Novel Von Hippelâ€“Lindau Point Mutation Presents as Apparently Sporadic Pheochromocytoma. Cancer Investigation, 2008, 26, 642-646.	1.3	2
61	Predictive molecular markers of anthracycline effectiveness in early breast cancer. European Journal of Cancer, Supplement, 2011, 9, 16-21.	2.2	1
62	Erratum to â€œDetection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinomaâ€•[Hum Pathol 40 (2009) 827-833]. Human Pathology, 2009, 40, 1212.	2.0	0
63	Management of Aromatase Inhibitor-Resistant Disease with Estrogen, Selective Estrogen Receptor Down-Regulators, and Other Agents. Current Breast Cancer Reports, 2011, 3, 24-33.	1.0	0
64	E16. Clinical implications of microRNAs in breast cancer. European Journal of Cancer, 2012, 48, S32-S34.	2.8	0
65	miRNAs in medullary thyroid carcinoma: when will they be relevant to the clinic?. International Journal of Endocrine Oncology, 2014, 1, 7-10.	0.4	0
66	Circulating Nucleic Acids (RNA/DNA) in Breast Cancer. , 2016, , 235-256.		0